Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 10/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918123 | 0.88 | PSEN1 (0.48) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL916914 | 0.86 | MEN1 (0.52) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL917493 | 0.85 | PSEN1 (0.51) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL917484 | 0.81 | PSEN1 (0.52) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL12942791 | 0.80 | PSEN1 (0.46) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL14606807 | 0.78 | POLB (0.42) | MEN1KMT2APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL917046 | 0.77 | PSEN1 (0.59) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL917362 | 0.76 | PSEN1 (0.54) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL917218 | 0.75 | PSEN1 (0.52) | APPMEN1KMT2APSEN1PSEN2 | |
| SCHEMBL917131 | 0.75 | PSEN1 (0.65) | MEN1KMT2APSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | APP 7/4885MEN1 2110/4885KMT2A 3148/4885 |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | APP 7/4885MEN1 2563/4885KMT2A 2774/4885 |
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | APP 7/4885MEN1 2110/4885KMT2A 3148/4885 |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | APP 7/4885MEN1 2110/4885KMT2A 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.